z-logo
Premium
Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage
Author(s) -
Santos Carlos A. Q.,
Brennan Daniel C.,
Saeed Mohammed J.,
Fraser Victoria J.,
Olsen Margaret A.
Publication year - 2016
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12706
Subject(s) - medicine , valganciclovir , serostatus , cohort , cytomegalovirus , retrospective cohort study , kidney transplantation , medical prescription , ganciclovir , transplantation , immunology , human cytomegalovirus , viral load , virus , herpesviridae , viral disease , pharmacology
We assembled a cohort of 21 117 kidney transplant patients from July 2006 to June 2011 with Medicare Part D coverage using US Renal Database System data to determine real‐world use of cytomegalovirus ( CMV ) prophylaxis. CMV prophylaxis was defined as filled prescriptions for daily oral valganciclovir (≤900 mg), ganciclovir (≤3 g), or valacyclovir (6–8 g) within 28 d of transplant. Multilevel logistic regression analyses were performed to determine factors associated with CMV prophylaxis. CMV prophylaxis (97% valganciclovir) was identified in 61% of kidney transplant recipients (median duration, 64 d); 71% of seronegative recipients of kidneys from seropositive donors (D+/R−); 63% of R+ patients; 60% of patients with unknown serostatus; and 34% of D−/R− patients. Variability in usage of prophylaxis among transplant centers was greater than variability within transplant centers. One in four transplant centers prescribed CMV prophylaxis to >60% of their D−/R− patients. CMV donor/recipient serostatus, lymphocyte‐depleting agents for induction and mycophenolate for maintenance were associated with CMV prophylaxis. CMV prophylaxis was commonly used among kidney transplant recipients. Routine prescription of CMV prophylaxis to D−/R− patients may have occurred in some transplant centers. Limiting unnecessary use of CMV prophylaxis may decrease healthcare costs and drug‐related harms.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here